Organon & Co. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding its debt reduction strategy after acquiring Dermavant [2] - Following the revelation of a 70% decrease in the regular quarterly dividend, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]